Psoriasis – Emerging Therapies – Cosentyx Launch Tracking Wave 1 (US)

LaunchTrends: Cosentyx (US) is a three-wave syndicated report series that specifically tracks the introduction of Novartis’s Cosentyx (secukinumab), a potent, subcutaneous IL-17 inhibitor approved for the treatment of psoriasis (PsO). This report series is based on primary research data collected at one month, six months, and one year post-commercial availability of Cosentyx. Along with awareness and sources of familiarity, the reports assess U.S. dermatologists’ trial, adoption, and use of Cosentyx, including anticipated future trends. The reports also provide information on product perceptions, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Novartis’s promotional efforts, and benchmarking against other previously launched immune agents.

Questions Answered:

  • Novartis launched Cosentyx in the US market as a treatment for moderate to severe PsO in March 2015. What is dermatologists’ level of awareness and familiarity with Cosentyx over the course of the following year?
  • Cosentyx enters a busy PsO market with five branded biologic/novel small molecule oral options, and an active pipeline. What are the perceived clinical advantages and disadvantages of Cosentyx compared with other marketed agents used to treat PsO? How are the trial and adoption of Cosentyx tracking compared with other product launches in the PsO market?
  • Cosentyx’s US label recommends use for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy, with the potential of use prior to the established PsO-treating biologics. Where do dermatologists expect Cosentyx to fit in the PsO treatment algorithm? What are the current prescribing trends among biologics/novel orals, and how do dermatologists anticipate they will change?
  • Novartis’ Cosentyx is the first IL-17-inhibiting psoriasis treatment to enter the market. What promotional messages and activities is Novartis employing in support of the Cosentyx launch?

Scope: 

Markets covered: United States.

Primary research: 75 dermatologists surveyed per report wave; 10 qualitative interviews with a subset of survey respondents.

Indication coverage: Psoriasis.

Table of contents

  • Psoriasis - Emerging Therapies - Cosentyx Launch Tracking Wave 1 (US)
    • Key Findings
      • Awareness and Perceptions of Cosentyx
      • Cosentyx Trial and Use
      • Competitive Landscape and Cosentyxu2019s Promotion
    • Benchmarking Cosentyx Launch Success vs. Analogue Immune Agents
      • Prescriber and Nonprescriber Profiles
        • Cosentyx: Differences Between Prescriber and Nonprescriber Profiles
      • Cosentyx Awareness and Perceptions
        • Unaided and Aided Awareness of Cosentyx
          • Awareness of Cosentyx
          • Familiarity with Cosentyx
          • Existence of Cosentyx Attributes That Dermatologists Were Not Aware Of
          • Existence of Cosentyx Attributes That Dermatologists Were Not Aware Of
        • Familiarity with Cosentyx
          • Unaided Awareness of Drugs Currently Available for PsO
        • Sources of Familiarity with Cosentyx
          • Physician opinion
        • Initial Reaction to and Interest in Cosentyx
          • Cosentyx Product Profile
          • Initial Reaction to Cosentyx After Viewing Product Profile
          • Interest Reaction to Cosentyx Based on the Following Attributes
          • Physician Interest in Learning More About Cosentyx
        • Impressions of Cosentyx
          • Physician-Rated Uniqueness of Cosentyx Compared with Other Available PsO Agents
          • Physician opinion
          • Physician opinion
          • Physician-Rated Risk-Benefit Ratio of Cosentyx
          • Physician opinion
        • Prescriber and Nonprescriber Profiles
          • Cosentyx: Differences Between Prescriber and Nonprescriber Profiles
      • Cosentyx Trial and Use
        • Willingness to Prescribe Cosentyx
          • Physician Willingness to Prescribe Cosentyx
          • Physician-Rated Willingness to Prescribe Cosentyx
        • Number of Patients Currently Receiving Cosentyx
          • Physician opinion
          • Use of Cosentyx by Disease Severity
          • Origination of Patients Treated with Cosentyx
        • Anticipated Cosentyx Use
          • Mean Cosentyx Starts and Anticipated Starts Within the Next Month
          • Physician opinion
          • Mean Number of Cosentyx Patient Inquiries per Physician, Wave 1
          • Result of Specific Patient Requests for Cosentyx, Wave 1
          • Physician opinion
          • Physician opinion
          • Candidates for Cosentyx by PsO Disease Severity
          • Candidates for Cosentyx by Treatment History
          • Cosentyx Line of Therapy
          • Cosentyx Line of Therapy If Price Were Not an Issue
        • Cosentyx Performance on Key Attributes
          • Physician opinion
          • Physician opinion
          • Physician-Rated Satisfaction with Cosentyx
      • Effectiveness of Face-to-Face Detailing for Cosentyx
        • Cosentyx Sales Representative Frequency and Reach
          • Physician opinion
          • Frequency of Dermatologist Contact with Cosentyx Representative
          • Physician opinion
          • Dermatologistsu2019 Receipt of Patient Education Materials/Starter Kits
          • Dermatologistsu2019 Use of Received Starter Kits to PsO patients
        • Satisfaction with Cosentyx Sales Representative
          • Cosentyx Sales Representative Performance
          • Cosentyx Sales Representative Performanceu2026In Their Own Words
        • Cosentyx Message Recall
          • Physician opinion
          • Physician opinion
          • Dermatologists Provided with Suggestions on Ideal Use of Cosentyx
      • Appendix
        • Primary Market Research
          • Years in Practice
          • Regional Distribution of Dermatologists
          • Practice Type
          • Practice Location
          • Mean Number of PsO Patients
        • Additional Information
          • Dermatologistsu2019 Awareness of Products in Development for PsO Treatment
          • Psoriasis Background: Definition and Types of Psoriasis
          • Psoriasis Background: Prevalence, Characteristics, and Treatment
          • Psoriasis Background: Biologics/Small Molecules Approved for Psoriasis
          • Psoriasis Market News
          • Report Abbreviations
          • Study Objectives
          • Preferred Biologics or Novel Oral Agents for Each Line
          • Patient Disease Severity
          • Prescription Drug Treatment by PsO Disease Severity
          • Opinions and Advice on Cosentyx for Treatment of PsO
          • Physician-Rated Managed Care Approval Process for Cosentyx
          • Dosage Administration to Patients Who Are/Were Receiving Cosentyx
          • Advice for Novartisu2026In Their Own Words
          • Defining Psoriasis Severityu2026In Their Own Words
          • Physician opinion
          • Physicians Enrolling Patients to Cosentyxu2019s CSP
          • Requirement for Managed Care Approval of Cosentyx Prescriptions
          • Products Currently in Clinical Trials for PsO Treatment
          • PsO Treatment Algorithmu2026In Their Own Words
          • Physician opinion
          • Brand Share of Biologics or Novel Oral Agents Used in PsO
          • Cosentyx Dosingu2026In Their Own Words
          • Cosentyx Managed Care Approval Processu2026In Their Own Words
          • Experience with Cosentyxu2019s CSP
          • Dermatologistsu2019 Familiarity with Products in Development
          • Physician opinion
          • Cosentyx Customer Support Programu2026In Their Own Words
          • Physician opinion
          • Patient Response to Biologics or Otezla
          • PsO Products in Developmentu2026In Their Own Words
          • Percentage of Patients Starting on Each Biologic/Otezla in the Past Year Who Received It as a First-Line Systemic Therapy
          • Physician opinion
          • Phototherapy Treatment by PsO Disease Severity
          • Percentage of Patients Who Discontinue on Treatment of Each Biologic/Otezla
          • Physician opinion
          • Efficacy Attributesu2019 Importance When Choosing a Biologic Agent
          • Safety/Tolerability Attributesu2019 Importance When Choosing a Biologic Agent
          • Biologics/Novel Oral Agents Discussed by Representatives
          • Pharmacology Attributesu2019 Importance When Choosing a Biologic Agent
          • Physician opinion
          • Patient Benefits Attributesu2019 Importance When Choosing a Biologic Agent
          • Physician Benefits Attributesu2019 Importance When Choosing a Biologic Agent
          • Statement Agreement
          • Statement Agreement

    launch Related Market Assessment Reports